Related Experiment Video
Updated: Sep 26, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeting ALK Rearrangements in NSCLC: Current State of the Art
Ling Peng1, Liping Zhu2, Yilan Sun1
1Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Abstract:
Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the approval of the first-generation ALK inhibitor crizotinib which achieved better results in prolonging the progression-free survival (PFS) compared with chemotherapy, a number of next-generation ALK inhibitors have been developed including ceritinib, alectinib, brigatinib, and ensartinib. Recently, a potent, third-generation ALK inhibitor, lorlatinib, has been approved by the Food and Drug Administration (FDA) for the first-line treatment of ALK-positive (ALK+) NSCLC. These drugs have manageable toxicity profiles. Responses to ALK inhibitors are however often not durable, and acquired resistance can occur as on-target or off-target alterations. Studies are underway to explore the mechanisms of resistance and optimal treatment options beyond progression. Efforts have also been undertaken to develop further generations of ALK inhibitors. This review will summarize the current situation of targeting the ALK signaling pathway.
Insights
Targeting anaplastic lymphoma kinase (ALK) with drugs has advanced non-small cell lung cancer (NSCLC) treatment. Ongoing research addresses resistance to ALK inhibitors to improve durable patient responses.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) alterations are key drivers in a subset of non-small cell lung cancer (NSCLC).
- ALK-targeted therapies have significantly improved outcomes compared to traditional chemotherapy.
- The evolution of ALK inhibitors spans from first-generation to recently approved third-generation agents.
Purpose of the Study:
- To review the current landscape of ALK-targeted therapies for NSCLC.
- To summarize the development and efficacy of successive generations of ALK inhibitors.
- To discuss challenges including drug resistance and future therapeutic directions.
Main Methods:
- Literature review of clinical trials and research studies on ALK inhibitors in NSCLC.
- Analysis of drug efficacy, toxicity profiles, and mechanisms of resistance.
- Synthesis of current data on first-, second-, and third-generation ALK inhibitors.
Main Results:
- First-generation ALK inhibitor crizotinib demonstrated improved progression-free survival (PFS) over chemotherapy.
- Next-generation inhibitors (ceritinib, alectinib, brigatinib, ensartinib) offer enhanced efficacy and broader activity.
- Third-generation lorlatinib is FDA-approved for first-line treatment, showing potent activity.
Conclusions:
- ALK inhibitors represent a major advancement in NSCLC treatment.
- Acquired resistance, both on-target and off-target, remains a significant clinical challenge.
- Further research is crucial for understanding resistance mechanisms and developing next-generation treatments for durable responses.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
